CompanyHealth
Olatec Therapeutics
Olatec Therapeutics is a clinical-stage biopharmaceutical company in New York developing a platform of oral NLRP3 inflammasome inhibitors to treat acute and chronic inflammatory diseases. Its lead compound, dapansutrile (OLT1177), is a selective small-molecule NLRP3 inhibitor that has shown clinical benefit and a clean safety profile across gout, heart failure and a broad range of inflammatory and neuroinflammatory conditions, positioning oral inflammasome blockade as a potential alternative to injectable IL-1 biologics.
2003Founded
New YorkHQ
$102,400,000+Total funding to date
biotechnlrp3 inhibitordapansutrileinflammasomeinflammationimmunology